iNDI ALFAtag cell lines for the iPSC Neurodegenetive Disease Initiative (iNDI) project
ID: 75N95025Q00078Type: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIDABethesda, MD, 20892, USA

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

PSC

IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS (6550)

Original Source

https://sam.gov/opp/c623062392a3441e915c68257da8dc00/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small businesses to provide iNDI ALFAtag cell lines for the iPSC Neurodegenerative Disease Initiative (iNDI) project. The primary objective of this procurement is to generate a collection of up to 230 genetically engineered isogenic cell lines related to Alzheimer's disease and related dementias, which will serve as a national cell repository for the scientific community. These cell lines will be utilized to characterize how genetic mutations affect disease-relevant cell types, with specific requirements for quality control and genetic validation processes. Interested vendors must submit their capability statements by December 27, 2024, at 12:00 PM Eastern Time, to Andrea Clay at amcgee@mail.nih.gov, and should include their company details and relevant qualifications.

    Point(s) of Contact
    Andrea Clay
    (301) 480-2449
    amcgee@nida.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Opera Phenix Plus High-Content Screening System (or equal)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small businesses to provide an Opera Phenix Plus High-Content Screening System or an equivalent product for the Intramural Center for Alzheimer’s and Related Dementias (CARD). The procurement aims to acquire a high-content imaging system capable of analyzing cellular samples, including organoids and tissue slices, to support research on neurodegenerative diseases. This initiative is critical for advancing the understanding of Alzheimer’s disease and related conditions through the analysis of induced pluripotent stem cells (iPSCs). Interested vendors must submit their capability statements by December 27, 2024, at 5 PM Eastern Time, to Iris Merscher at iris.merscher@nih.gov, ensuring compliance with the specified requirements and guidelines.
    The Role of Mitochondrial Genetic Variation in Dementia
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small business sources for a project titled "The Role of Mitochondrial Genetic Variation in Dementia." The objective of this procurement is to obtain laboratory analysis of mitochondrial genetic variation in brain tissue samples from dementia patients, which will aid in understanding the relationship between mitochondrial function and Alzheimer's disease. This initiative is crucial as it aims to explore potential pathways to dementia through the examination of mitochondrial DNA mutations and oxidative capacity in patient samples. Interested contractors must submit their responses by January 2, 2025, to Kevin Alvarez at kevin.alvarez@nih.gov, detailing their capabilities and business size status, as this opportunity is particularly focused on small businesses.
    SOURCES SOUGHT: Mass Spectrometer
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking information from qualified small businesses regarding their capabilities to provide a mass spectrometer system for the iPSC Neurodegenerative Diseases Initiative (INDI) Project. The procurement aims to acquire advanced mass spectrometry equipment that will facilitate the measurement of neurodegeneration-related mutations and their effects on protein networks in disease-relevant cells. This equipment is critical for advancing research in neurodegenerative diseases, particularly within the new Center for Alzheimer’s Disease and Related Dementias (CARD). Interested parties must submit their capability statements to Hashim Dasti at hashim.dasti@nih.gov by December 31, 2024, at 11 AM Eastern Time, adhering to specified formatting guidelines and including relevant business information.
    Genotyping Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for genotyping services to analyze 1,500 DNA samples related to Alzheimer's Disease and Related Dementias research. The selected contractor will perform microarray genotyping using Illumina Infinium Global Diversity + Neurobooster Arrays, ensuring quality control and timely reporting of results to support the National Institute on Aging's objectives in advancing research in this critical area. Proposals must be submitted electronically by 11:00 A.M. Eastern on December 27, 2024, to Hashim Dasti at hashim.dasti@nih.gov, with the anticipated award being a firm fixed-price purchase order for a period of twelve months after receipt of order. Interested parties should ensure compliance with all applicable federal regulations and provide evidence of their capability to fulfill the requirements outlined in the solicitation.
    Long Sequencing Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) NIDA, is seeking qualified small businesses to provide Long Sequencing Kits as part of a Sources Sought notice. The primary objective of this procurement is to acquire kits that facilitate long read sequencing for analyzing biomarkers related to Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD), which are crucial for understanding disease progression and therapeutic efficacy. The kits must meet specific technical requirements, including compatibility with Nanopore PromethION 48 sequencers and the ability to generate substantial sequencing data in real-time. Interested parties must submit their capability statements to Andrea Clay at amcgee@nida.nih.gov by December 31, 2024, at 12:00 PM Eastern Time, as this notice is strictly for research and information purposes and does not obligate the government to award a contract.
    cDNA-PCR Sequencing Kits for long-read sequencing.
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of cDNA-PCR Sequencing Kits for long-read sequencing, as part of a combined synopsis/solicitation. The primary objective is to acquire Promethion Flow Cell packs and sequencing kits to support high-throughput sequencing efforts aimed at advancing research on neurodegenerative diseases, particularly Alzheimer's disease. This procurement is crucial for the Center for Alzheimer’s Disease and Related Dementias (CARD) and is expected to facilitate the identification of causative genes and potential therapeutic targets. Interested vendors must submit their quotations by 5:00 p.m. Eastern Time on December 30, 2024, referencing Solicitation Number 75N95025Q00008, and can direct inquiries to Iris Merscher at iris.merscher@nih.gov or by phone at 301-827-2547.
    Single-plex NULISApcr Absolute Quantification Assay of HDGFL2 in Plasma Samples
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is soliciting proposals for the development of a single-plex NULISApcr absolute quantification assay to measure HDGFL2 levels in plasma samples, linked to TDP-43 dysfunction associated with Alzheimer’s Disease and Related Dementias (ADRD). The project aims to establish a biomarker for HDGFL2, which is crucial for advancing research and treatment in neurological disorders. The anticipated contract will be a firm fixed-price purchase order with a performance period of twelve months, and proposals must be submitted electronically to Emily Palombo at emily.palombo@nih.gov by 9:00 a.m. Eastern Daylight Time on December 23, 2024. Interested parties should ensure compliance with all relevant FAR provisions and include necessary certifications in their submissions.
    Assay Kits for Lumipulse instrument
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of assay kits for the Lumipulse instrument, aimed at quantifying specific biomarkers related to Alzheimer's Disease. The acquisition includes a total of 4,410 assays for biomarkers abeta42, abeta40, and pTau 217, which will be utilized in research involving stored samples from the Baltimore Longitudinal Study of Aging (BLSA) to assess cognitive decline and neurodegeneration. This procurement is critical for advancing Alzheimer’s research and will be awarded as a firm fixed-price purchase order, with quotations due by 5:00 p.m. Eastern Time on January 8, 2025. Interested vendors should contact Iris Merscher at iris.merscher@nih.gov for further details.
    A--National Gene Vector Biorepository
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for the National Gene Vector Biorepository (NGVB) to support gene therapy research for the National Heart, Lung, and Blood Institute (NHLBI). The contract aims to provide essential resources and services, including administrative management, core laboratory activities, and compliance with FDA regulations and Good Laboratory Practices (GLP). This initiative is crucial for advancing gene therapy capabilities and ensuring the proper archiving of biological specimens and development of assays. Proposals must be submitted by January 10, 2025, and should include detailed technical and business plans, with specific formatting guidelines and a budget submission required. For further inquiries, interested parties can contact Ethan J. Mueller at ethan.mueller@nih.gov or +1 301 496 2153.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Chemistry, Manufacturing, and Controls (CMC) services related to the development of drug products. The objective of this procurement is to secure high-quality formulated drug products to support preclinical, IND-enabling, and clinical studies, ensuring compliance with current Good Manufacturing Practices (cGMP). This initiative is critical for advancing therapeutic development and enhancing the drug development pipeline, which is vital for public health. Proposals are due by February 3, 2025, with a contract period extending from September 30, 2025, to July 31, 2031, and a maximum funding amount of $49,885,703. Interested parties can reach out to Michelle Cecilia at michelle.cecilia@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.